[105]
Dr. Caldwell maintains that Dr. Klibanov's statement that it would be very difficult to design a process of isolating enantiomers is not directed at the mere separation of racemic ofloxacin into its optical isomers but instead is directed to the development of processes to produce the enantiomer of interest
on a commercially economical basis
, after a compound has been isolated and tested to confirm its pharmacological activity. Dr. Caldwell then asserts that the three processes set out in the disclosure of the '080 patent are "production processes" rather than merely resolution processes.